Aralez Pharmaceuticals Company Profile (NASDAQ:ARLZ)

About Aralez Pharmaceuticals (NASDAQ:ARLZ)

Aralez Pharmaceuticals logoAralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ARLZ
  • CUSIP: 73941U10
  • Web:
  • Market Cap: $95.59 million
  • Outstanding Shares: 66,848,000
Average Prices:
  • 50 Day Moving Avg: $1.19
  • 200 Day Moving Avg: $1.54
  • 52 Week Range: $0.95 - $5.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.38
  • P/E Growth: -0.03
Sales & Book Value:
  • Annual Revenue: $87.22 million
  • Price / Sales: 1.10
  • Book Value: $1.12 per share
  • Price / Book: 1.28
  • EBIDTA: ($55,020,000.00)
  • Net Margins: -122.35%
  • Return on Equity: -90.17%
  • Return on Assets: -22.15%
  • Debt-to-Equity Ratio: 3.66%
  • Current Ratio: 1.11%
  • Quick Ratio: 1.04%
  • Average Volume: 628,727 shs.
  • Beta: 1.34
  • Short Ratio: 4.84

Frequently Asked Questions for Aralez Pharmaceuticals (NASDAQ:ARLZ)

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ."

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.01. The business had revenue of $27.62 million for the quarter, compared to analysts' expectations of $21.37 million. Aralez Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 122.35%. Aralez Pharmaceuticals's revenue for the quarter was up 119.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.27) earnings per share. View Aralez Pharmaceuticals' Earnings History.

When will Aralez Pharmaceuticals make its next earnings announcement?

Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Aralez Pharmaceuticals.

Where is Aralez Pharmaceuticals' stock going? Where will Aralez Pharmaceuticals' stock price be in 2017?

3 analysts have issued 12 month target prices for Aralez Pharmaceuticals' stock. Their predictions range from $4.00 to $12.00. On average, they anticipate Aralez Pharmaceuticals' stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Aralez Pharmaceuticals.

Who are some of Aralez Pharmaceuticals' key competitors?

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the folowing people:

  • Arthur S. Kirsch, Independent Chairman of the Board
  • Andrew I. Koven, President, Chief Business Officer
  • Adrian Adams, Chief Executive Officer, Director
  • Scott J. Charles, Chief Financial Officer, Senior Vice President
  • Jennifer Lou Armstrong, Executive Vice President - Human Resources and Administration
  • Eric L. Trachtenberg, Chief Compliance Officer, General Counsel, Corporate Secretary
  • Mark A. Glickman, Chief Commercial Officer
  • James Patrick Tursi M.D., Chief Medical Officer
  • Kenneth B. Lee Jr., Lead Independent Director
  • Neal Franklin Fowler, Independent Director

Who owns Aralez Pharmaceuticals stock?

Aralez Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (3.09%), GSA Capital Partners LLP (0.82%), JW Asset Management LLC (0.49%), Dimensional Fund Advisors LP (0.48%), FMR LLC (0.40%) and Contrarius Investment Management Ltd (0.33%). Company insiders that own Aralez Pharmaceuticals stock include Adrian Adams, Andrew I Koven, Arthur S Kirsch, Eric Trachtenberg, James Patrick Tursi, Jason Aryeh, John R Plachetka, Kenneth B Lee Jr, Robert Paul Harris, Scott J Charles and Seth Rudnick. View Institutional Ownership Trends for Aralez Pharmaceuticals.

Who sold Aralez Pharmaceuticals stock? Who is selling Aralez Pharmaceuticals stock?

Aralez Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, JW Asset Management LLC, Wells Fargo & Company MN, Virtu KCG Holdings LLC, Goldman Sachs Group Inc., Wsfs Capital Management LLC and FMR LLC. Company insiders that have sold Aralez Pharmaceuticals stock in the last year include Andrew I Koven, Eric Trachtenberg, Jason Aryeh, Robert Paul Harris and Scott J Charles. View Insider Buying and Selling for Aralez Pharmaceuticals.

Who bought Aralez Pharmaceuticals stock? Who is buying Aralez Pharmaceuticals stock?

Aralez Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Intrinsic Edge Capital Management LLC, Franklin Street Advisors Inc. NC, Salzhauer Michael and Isthmus Partners LLC. Company insiders that have bought Aralez Pharmaceuticals stock in the last two years include Adrian Adams, Andrew I Koven, Arthur S Kirsch, Eric Trachtenberg, James Patrick Tursi, Kenneth B Lee Jr, Scott J Charles and Seth Rudnick. View Insider Buying and Selling for Aralez Pharmaceuticals.

How do I buy Aralez Pharmaceuticals stock?

Shares of Aralez Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aralez Pharmaceuticals' stock price today?

One share of Aralez Pharmaceuticals stock can currently be purchased for approximately $1.43.

MarketBeat Community Rating for Aralez Pharmaceuticals (NASDAQ ARLZ)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  208
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aralez Pharmaceuticals (NASDAQ:ARLZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (459.44% upside)

Analysts' Ratings History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Chardan CapitalLower Price TargetBuy -> Buy$5.50 -> $4.00HighView Rating Details
4/10/2017Bloom BurtonUpgradeAccumulate -> BuyMediumView Rating Details
10/10/2016GuggenheimSet Price TargetBuy$12.00N/AView Rating Details
3/16/2016Dundee SecuritiesLower Price TargetBuy$10.00 -> $9.00N/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Earnings by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Earnings History by Quarter for Aralez Pharmaceuticals (NASDAQ ARLZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017N/AView Earnings Details
8/9/20176/30/2017($0.41)($0.42)$21.37 million$27.62 millionViewListenView Earnings Details
5/9/20173/31/2017($0.40)($0.42)$20.23 million$26.00 millionViewListenView Earnings Details
3/13/201712/31/2016($0.26)($0.37)$21.86 million$20.00 millionViewListenView Earnings Details
11/7/2016Q316($0.32)($0.32)$12.23 million$136.00 millionViewListenView Earnings Details
8/9/2016Q216($0.19)($0.27)$9.70 million$12.60 millionViewListenView Earnings Details
5/10/2016Q116($0.53)($0.73)$9.70 million$8.10 millionViewListenView Earnings Details
3/15/2016Q415($0.28)($0.40)$9.25 million$5.97 millionViewListenView Earnings Details
11/9/2015Q315($0.26)($0.25)$5.20 million$5.80 millionViewListenView Earnings Details
8/10/2015Q215$0.04($0.50)$4.60 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115$0.08$0.01$4.70 million$4.40 millionViewListenView Earnings Details
3/9/2015Q414$0.17$0.21$8.55 million$9.90 millionViewListenView Earnings Details
11/6/2014Q314$0.11$0.20$7.50 million$7.50 millionViewListenView Earnings Details
8/7/2014Q214$0.05$0.09$7.10 million$7.40 millionViewListenView Earnings Details
5/8/2014Q1($0.06)$0.09$5.50 million$7.55 millionViewListenView Earnings Details
3/5/2014Q413($0.05)($0.07)$4.35 million$4.70 millionViewListenView Earnings Details
11/6/2013Q313($0.09)($0.16)$3.25 million$2.60 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.20)($0.13)$1.30 million$1.70 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.19)($0.19)$1.43 million$1.40 millionViewListenView Earnings Details
3/6/2013Q4 2012($0.21)($0.20)$1.46 million$1.40 millionViewListenView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.73 million$0.90 millionViewN/AView Earnings Details
8/1/2012($0.25)($0.17)ViewN/AView Earnings Details
5/1/2012($0.28)($0.28)ViewN/AView Earnings Details
2/28/2012$2.00$2.04ViewN/AView Earnings Details
11/3/2011($0.24)($0.24)ViewN/AView Earnings Details
7/28/2011($0.19)($0.21)ViewN/AView Earnings Details
5/5/2011($0.23)($0.19)ViewN/AView Earnings Details
3/9/2011$0.56$0.61ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aralez Pharmaceuticals (NASDAQ:ARLZ)
2017 EPS Consensus Estimate: ($1.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.48)($0.48)($0.48)
Q2 20171($0.43)($0.43)($0.43)
Q3 20171($0.46)($0.46)($0.46)
Q4 20171($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)


Dividend History by Quarter for Aralez Pharmaceuticals (NASDAQ ARLZ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 23.79%
Insider Trades by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Institutional Ownership by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Insider Trades by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/28/2017Scott J CharlesCFOSell10,804$1.25$13,505.00View SEC Filing  
6/23/2017Eric TrachtenbergInsiderSell7,720$1.33$10,267.60View SEC Filing  
6/15/2017Arthur S KirschDirectorBuy15,000$1.15$17,250.00View SEC Filing  
6/14/2017Arthur S KirschDirectorBuy50,000$1.17$58,500.00View SEC Filing  
6/5/2017Andrew I KovenInsiderSell161,906$1.28$207,239.68View SEC Filing  
5/23/2017Jason AryehDirectorSell388,685$1.44$559,706.40View SEC Filing  
3/20/2017Andrew I KovenInsiderSell7,825$2.41$18,858.25View SEC Filing  
3/20/2017Scott J CharlesCFOSell5,205$2.41$12,544.05View SEC Filing  
3/15/2017Adrian AdamsCEOBuy500,000$2.46$1,230,000.00View SEC Filing  
3/15/2017Arthur S KirschDirectorBuy45,000$2.27$102,150.00View SEC Filing  
3/15/2017James Patrick TursiInsiderBuy4,750$2.11$10,022.50View SEC Filing  
11/29/2016Robert Paul HarrisDirectorSell104,778$4.99$522,842.22View SEC Filing  
11/28/2016Robert Paul HarrisDirectorSell20,000$4.65$93,000.00View SEC Filing  
11/14/2016Kenneth B Lee JrDirectorBuy1,000$4.95$4,950.00View SEC Filing  
11/11/2016Seth RudnickDirectorBuy30,000$4.77$143,100.00View SEC Filing  
9/15/2016Robert Paul HarrisDirectorSell150,000$5.82$873,000.00View SEC Filing  
5/20/2016James Patrick TursiInsiderBuy10,000$3.75$37,500.00View SEC Filing  
5/16/2016Eric TrachtenbergInsiderBuy10,000$3.76$37,600.00View SEC Filing  
5/13/2016Kenneth B Lee JrDirectorBuy1,000$3.50$3,500.00View SEC Filing  
5/12/2016Andrew I KovenInsiderBuy71,500$3.49$249,535.00View SEC Filing  
5/12/2016Arthur S KirschDirectorBuy27,500$3.49$95,975.00View SEC Filing  
5/12/2016Scott J CharlesCFOBuy50,000$3.49$174,500.00View SEC Filing  
12/3/2015John R PlachetkaMajor ShareholderSell23,479$8.14$191,119.06View SEC Filing  
11/13/2015John R PlachetkaMajor ShareholderSell150,000$7.00$1,050,000.00View SEC Filing  
11/12/2015Adrian AdamsCEOBuy1,000,000$6.55$6,550,000.00View SEC Filing  
9/10/2015John E. BarnhardtVPSell18,322$8.78$160,867.16View SEC Filing  
6/18/2015John G FortInsiderSell78,905$10.93$862,431.65View SEC Filing  
6/3/2015Gilda Marie ThomasInsiderSell23,555$7.53$177,369.15View SEC Filing  
4/15/2015Gilda Marie ThomasInsiderSell25,000$8.61$215,250.00View SEC Filing  
3/17/2015Gilda Marie ThomasInsiderSell50,000$7.51$375,500.00View SEC Filing  
1/2/2015Gilda Marie ThomasVPSell25,000$7.91$197,750.00View SEC Filing  
12/1/2014Par Investment Partners LpMajor ShareholderBuy500,000$7.50$3,750,000.00View SEC Filing  
11/18/2014John R PlachetkaCEOSell50,000$9.00$450,000.00View SEC Filing  
11/6/2014John R PlachetkaCEOSell50,000$9.08$454,000.00View SEC Filing  
10/9/2014John R PlachetkaCEOSell50,000$8.12$406,000.00View SEC Filing  
10/8/2014John R PlachetkaCEOSell32,227$8.16$262,972.32View SEC Filing  
9/30/2014John R PlachetkaCEOSell50,000$7.48$374,000.00View SEC Filing  
9/29/2014John R PlachetkaCEOSell38,298$7.53$288,383.94View SEC Filing  
9/15/2014Dennis L McnamaraEVPSell4,275$7.85$33,558.75View SEC Filing  
9/9/2014John R PlachetkaCEOSell50,000$8.24$412,000.00View SEC Filing  
9/8/2014John R PlachetkaCEOSell30,000$8.30$249,000.00View SEC Filing  
8/25/2014John E BarnhardtVPSell4,293$8.25$35,417.25View SEC Filing  
8/20/2014John R PlachetkaCEOSell50,000$7.78$389,000.00View SEC Filing  
8/8/2014John R PlachetkaCEOSell50,000$7.75$387,500.00View SEC Filing  
7/30/2014John R PlachetkaCEOSell50,000$7.34$367,000.00View SEC Filing  
7/9/2014John R PlachetkaCEOSell50,000$8.88$444,000.00View SEC Filing  
7/8/2014John R PlachetkaCEOSell33,551$8.87$297,597.37View SEC Filing  
7/2/2014William L HodgesCFOSell11,414$9.05$103,296.70View SEC Filing  
6/23/2014John E BarnhardtVPSell27,484$8.80$241,859.20View SEC Filing  
6/23/2014William L HodgesCFOSell5,688$9.05$51,476.40View SEC Filing  
6/20/2014William L HodgesCFOSell50,000$9.05$452,500.00View SEC Filing  
6/19/2014William L HodgesCFOSell9,516$9.05$86,119.80View SEC Filing  
6/17/2014William L HodgesCFOSell112,156$9.03$1,012,768.68View SEC Filing  
6/16/2014Dennis L McnamaraEVPSell15,100$9.06$136,806.00View SEC Filing  
6/11/2014Arthur S KirschDirectorSell9,430$9.30$87,699.00View SEC Filing  
6/5/2014Arthur S KirschDirectorSell2,500$8.67$21,675.00View SEC Filing  
6/2/2014Arthur S KirschDirectorSell2,500$8.73$21,825.00View SEC Filing  
5/27/2014Arthur S KirschDirectorSell10,000$8.38$83,800.00View SEC Filing  
5/22/2014John BarnhardtVPSell77,840$8.31$646,850.40View SEC Filing  
5/16/2014John FortInsiderSell4,000$8.49$33,960.00View SEC Filing  
5/16/2014William HodgesCFOSell71,003$8.16$579,384.48View SEC Filing  
4/24/2014John FortInsiderSell13,725$9.61$131,897.25View SEC Filing  
12/20/2013John FortInsiderSell22,500$9.63$216,675.00View SEC Filing  
7/17/2013Par Investment Partners LpMajor ShareholderBuy90,000$5.25$472,500.00View SEC Filing  
12/27/2012John E BarnhardtVPSell5,219$5.25$27,399.75View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Latest Headlines for Aralez Pharmaceuticals (NASDAQ:ARLZ)
DateHeadline logoAnalyzing Aralez Pharmaceuticals (ARLZ) and The Competition - September 11 at 2:24 AM logoContrasting Eli Lilly and (LLY) and Aralez Pharmaceuticals (ARLZ) - September 7 at 2:20 PM logoETFs with exposure to Aralez Pharmaceuticals, Inc. : September 5, 2017 - September 5 at 10:42 PM logoRecent Developments in the Pharmaceutical Industry - September 5 at 5:38 PM logoOutside the Box: Here’s how Republicans and Democrats can come together to fix health care - August 23 at 6:10 AM logoEli Lilly and (LLY) versus Aralez Pharmaceuticals (ARLZ) Head to Head Analysis - August 10 at 2:38 PM logoAralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Price Target Cut to $4.00 by Analysts at Chardan Capital - August 10 at 2:16 PM logoEdited Transcript of ARLZ earnings conference call or presentation 9-Aug-17 1:00pm GMT - August 9 at 9:15 PM logoAralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Releases Earnings Results, Misses Expectations By $0.01 EPS - August 9 at 3:24 PM logoAralez Pharmaceuticals Inc (NASDAQ:ARLZ) to Release Earnings on Wednesday - August 2 at 7:10 AM logoAralez Pharmaceuticals Inc. (ARLZ) CFO Sells $13,505.00 in Stock - July 28 at 7:50 PM logoAralez: A Quick Overview Of The Investment Thesis - Seeking Alpha - July 25 at 8:57 PM logoShould You Be Worried About Your Heartburn Medication Causing Dementia? - July 22 at 3:38 AM logoAralez Pharmaceuticals Inc. (ARLZ) Short Interest Update - July 16 at 7:06 AM logoARLZ: Promising Early Data Following Launch of Zontivity®; VIMOVO® Patents Upheld - July 10 at 9:04 PM logoAralez Pharmaceuticals Inc. (ARLZ) Insider Sells $10,267.60 in Stock - June 23 at 7:52 PM logoAralez Pharmaceuticals Inc. (ARLZ) Director Arthur S. Kirsch Purchases 15,000 Shares - June 19 at 7:40 AM logoArthur S. Kirsch Acquires 50,000 Shares of Aralez Pharmaceuticals Inc. (ARLZ) Stock - June 16 at 8:32 AM logoAralez Pharmaceuticals Inc. (ARLZ) Downgraded to Strong Sell at ValuEngine - June 12 at 11:36 PM logoAralez Pharmaceuticals Inc. (ARLZ) Sees Significant Decrease in Short Interest - June 12 at 7:20 AM logoAralez Pharmaceuticals (ARLZ) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 8 at 4:21 PM logoAralez Pharma (ARLZ) Launchs Zontivity in the US - - June 7 at 3:47 PM logoAralez Announces Board Member Resignation - June 7 at 6:35 AM logoAralez Announces National U.S. Commercial Launch Of Zontivity - June 7 at 6:35 AM logoInsider Selling: Aralez Pharmaceuticals Inc (ARLZ) Insider Sells 161,906 Shares of Stock - June 6 at 10:28 PM logoJason Aryeh Sells 388,685 Shares of Aralez Pharmaceuticals Inc (ARLZ) Stock - May 24 at 10:22 AM logoAralez Pharmaceuticals Inc to Post Q2 2017 Earnings of ($0.43) Per Share, Zacks Investment Research Forecasts (ARLZ) - May 17 at 8:08 AM logoForm 4 Aralez Pharmaceuticals For: May 11 Filed by: Armstrong Jennifer Lou - May 13 at 2:44 AM logoToday's Research Reports on Stocks to Watch: DryShips and Aralez Pharmaceuticals - May 12 at 9:42 PM logoAralez Pharmaceuticals, Inc. :ARLZ-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 4:10 PM logoEdited Transcript of ARLZ earnings conference call or presentation 9-May-17 1:00pm GMT - May 10 at 8:51 PM logoAralez Pharmaceuticals Inc (ARLZ) Announces Earnings Results - May 9 at 11:24 AM logoAralez Reports First Quarter 2017 Financial Results - May 9 at 9:14 AM logoInvestor Network: Aralez Pharmaceuticals Inc. to Host Earnings Call - May 9 at 9:14 AM logoAralez Pharmaceuticals reports 1Q loss - May 9 at 8:59 AM logoAralez Pharmaceuticals Inc (ARLZ) to Release Earnings on Tuesday - May 7 at 7:10 AM logoAralez Announces Voting Results From 2017 Annual And Special Meeting Of Shareholders - PR Newswire (press release) - May 3 at 8:41 PM logoAralez Announces Voting Results From 2017 Annual And Special Meeting Of Shareholders - May 3 at 8:41 PM logoAralez Pharmaceuticals Inc (ARLZ) Short Interest Update - April 13 at 7:39 AM logoShort Interest in Aralez Pharmaceuticals Inc (ARLZ) Drops By 11.3% - April 10 at 9:50 PM logoAralez Pharma (ARLZ) to Reduce Workforce by 32% as Part of Cost Savings Program - - April 7 at 8:04 AM logoWhy Did Aralez's CEO Buy 500,000 Shares On March 15? - March 27 at 3:43 PM logoAralez Pharmaceuticals (ARLZ): Adrian Adams CEO Purchased 500,000 Shares Last Week: An Update And Interview - March 25 at 8:36 PM logoARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E - March 23 at 10:04 PM logoAndrew I. Koven Sells 7,825 Shares of Aralez Pharmaceuticals Inc (ARLZ) Stock - March 22 at 8:34 PM logoAralez Pharmaceuticals Inc (ARLZ) CFO Sells $12,544.05 in Stock - March 22 at 8:32 PM logoAralez Pharmaceuticals Inc (ARLZ) Price Target Cut to $5.50 by Analysts at Chardan Capital - March 21 at 7:58 AM logoAralez Pharmaceuticals Inc (ARLZ) Forecasted to Post Q1 2017 Earnings of ($0.48) Per Share - March 20 at 9:55 AM logoAralez CEO Purchases 500,000 Shares Of Company Common Stock On Open Market - March 20 at 8:34 AM logoAralez Pharmaceuticals Inc (ARZ) Director Buys C$11,850.00 in Stock - March 17 at 9:07 PM



Aralez Pharmaceuticals (ARLZ) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff